IN2012DN01913A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01913A
IN2012DN01913A IN1913DEN2012A IN2012DN01913A IN 2012DN01913 A IN2012DN01913 A IN 2012DN01913A IN 1913DEN2012 A IN1913DEN2012 A IN 1913DEN2012A IN 2012DN01913 A IN2012DN01913 A IN 2012DN01913A
Authority
IN
India
Prior art keywords
derivatives
stearoyl
modulate
activity
coa desaturase
Prior art date
Application number
Inventor
Natalie Dales
Jianmin Fu
Qi Jia
Natalia Pokrovskaia
Shaoyi Sun
Zaihui Zhang
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43066810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN01913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of IN2012DN01913A publication Critical patent/IN2012DN01913A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
IN1913DEN2012 2009-10-01 2010-10-01 IN2012DN01913A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24763409P 2009-10-01 2009-10-01
PCT/EP2010/064672 WO2011039358A1 (en) 2009-10-01 2010-10-01 Pyrazole derivatives which modulate stearoyl-coa desaturase

Publications (1)

Publication Number Publication Date
IN2012DN01913A true IN2012DN01913A (en) 2015-07-24

Family

ID=43066810

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1913DEN2012 IN2012DN01913A (en) 2009-10-01 2010-10-01

Country Status (22)

Country Link
US (1) US20130011361A1 (en)
EP (1) EP2483264A1 (en)
JP (1) JP2013506638A (en)
KR (1) KR20120080226A (en)
CN (1) CN102574841A (en)
AU (1) AU2010302577A1 (en)
BR (1) BR112012007509A2 (en)
CA (1) CA2776294A1 (en)
CL (1) CL2012000797A1 (en)
CO (1) CO6761294A2 (en)
CR (1) CR20120134A (en)
EA (1) EA201200545A1 (en)
EC (1) ECSP12011837A (en)
IL (1) IL218294A0 (en)
IN (1) IN2012DN01913A (en)
MA (1) MA33693B1 (en)
MX (1) MX2012003938A (en)
PE (1) PE20121439A1 (en)
SG (1) SG178869A1 (en)
TN (1) TN2012000085A1 (en)
WO (1) WO2011039358A1 (en)
ZA (1) ZA201201390B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103998027A (en) 2011-10-15 2014-08-20 霍夫曼-拉罗奇有限公司 Methods of using SCD1 antagonists for cancer therapy
CN110392833A (en) 2017-01-06 2019-10-29 优曼尼蒂治疗公司 The method for treating nervous disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CA3094527A1 (en) * 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1171465E (en) 1999-03-29 2004-12-31 Uutech Ltd ANALYSIS OF A GASTRIC INHIBITOR AND THEIR USE FOR THE TREATMENT OF DIABETES
ES2307534T3 (en) 1999-09-28 2008-12-01 Bayer Corporation RECEIVER AGONISTS 3 (R3) OF THE ACTIVATOR PEPTIDE OF THE HYPOPHYSIARY CYCLASS ADENYLATE (PACAP) AND ITS PHARMACOLOGICAL USE METHODS.
JP2003533978A (en) 2000-02-24 2003-11-18 ゼノン ジェネティクス，インコーポレイテッド Methods and compositions using stearoyl-CoA desaturases to identify triglyceride-reducing therapeutics
AU2001289457A1 (en) 2000-09-26 2002-04-08 Xenon Genetics Inc. Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626592A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
RU2009109147A (en) * 2006-08-15 2010-09-27 Новартис АГ (CH) ORGANIC COMPOUNDS
CN101506203B (en) * 2006-08-24 2013-10-16 诺瓦提斯公司 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other syndromes
JP5351025B2 (en) * 2006-09-22 2013-11-27 ノバルティス アーゲー Heterocyclic organic compounds
US8068738B2 (en) * 2007-02-21 2011-11-29 Tte Technology, Inc. System and method for decoding infra-red (IR) signals
MX2010009158A (en) * 2008-02-20 2010-09-24 Novartis Ag Heterocyclic inhibitors of stearoyl-coa desaturase.

Also Published As

Publication number Publication date
ECSP12011837A (en) 2012-06-29
EP2483264A1 (en) 2012-08-08
US20130011361A1 (en) 2013-01-10
EA201200545A1 (en) 2012-12-28
KR20120080226A (en) 2012-07-16
CA2776294A1 (en) 2011-04-07
CL2012000797A1 (en) 2013-08-09
CO6761294A2 (en) 2013-09-30
TN2012000085A1 (en) 2013-09-19
JP2013506638A (en) 2013-02-28
WO2011039358A1 (en) 2011-04-07
BR112012007509A2 (en) 2016-11-22
PE20121439A1 (en) 2012-11-06
AU2010302577A1 (en) 2012-03-15
MA33693B1 (en) 2012-10-01
ZA201201390B (en) 2012-10-31
MX2012003938A (en) 2012-08-03
CR20120134A (en) 2012-05-17
SG178869A1 (en) 2012-04-27
IL218294A0 (en) 2012-04-30
CN102574841A (en) 2012-07-11

Similar Documents

Publication Publication Date Title
WO2009156484A3 (en) Organic compounds
JO3014B1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
MX2009003080A (en) Heterocyclic organic compounds.
MX2009006728A (en) 2-substituted 5-membered heterocycles as scd inhibitors.
MY181898A (en) Heterocyclic compounds and uses thereof
WO2007143597A3 (en) Organic compounds
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
MX2012004114A (en) Heterocyclic compounds useful as pdk1 inhibitors.
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
MX2011013577A (en) Compositions and methods for treating amyotrophic lateral sclerosis.
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
TN2012000085A1 (en) Pyrazole derivatives which modulate stearoyl-coa desaturase
IN2012DN03404A (en)
MX342239B (en) Compositions and methods for the diagnosis and treatment of tumor.
MX2011013324A (en) Use of substituted oxindole derivatives for the treatment and prophylaxis of pain.
WO2011116351A3 (en) Methods and compositions for the treatment of cancer
MX2013005699A (en) Stable preserved compositions if interferon-beta.
TN2010000598A1 (en) Organic compounds
TN2010000378A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
TN2010000354A1 (en) Amide derivatives as positive allosteric modulators and methods of use thereof
UA47407U (en) Nitrilopyridine derivatives